{"id":4340,"date":"2026-02-08T15:31:37","date_gmt":"2026-02-08T10:01:37","guid":{"rendered":"https:\/\/www.entrepreneurindia.co\/blogs\/?p=4340"},"modified":"2026-03-09T12:49:09","modified_gmt":"2026-03-09T07:19:09","slug":"biopharma-ayush-manufacturing","status":"publish","type":"post","link":"https:\/\/www.entrepreneurindia.co\/blogs\/biopharma-ayush-manufacturing\/","title":{"rendered":"Biopharma & AYUSH Manufacturing: New Business Opportunities After Budget 2026"},"content":{"rendered":"

The ecosystem of India’s pharmaceutical and traditional medicine has passed a phase of a different structure. The industry that was previously a volume-intensive, formulation-intensive industry is being re-packaged as a science-based, export-focused and quality-insured manufacturing hub. The new policy orientation as indicated by the Union Budget 2026-27 of India is a firm thrust towards the empowerment of biopharma, modernisation of AYUSH production, and creation of a globally reputable certification and testing ecosystem.<\/p>\n

To startups, MSMEs, and first-generation entrepreneurs, such a shift provides a new category of business opportunities that are capital-efficient, margin-resistent, and scalable, as long as it is coupled with feasibility discipline and not enthusiasm per se. Instead of the traditional pharma entry routes where the players are large in terms of market share, the current biopharma & AYUSH manufacturing provide a variety of entry points, including intermediates, contract manufacturing, extracts, testing services, and export-oriented niche.<\/p>\n

\n
\n

Table of Contents<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n